Kun elektronisk udgave - Sundhedsstyrelsen

More documents

Recommendations

Info

Bilag 7ReferencerThe Age-Related Eye Disease Study Research Group. A randomized, placebocontrolled,clinical trial of high-dose supplementation with vitaminsC and E and betacarotene for age-related cataract and vision loss: AREDSreport no. 8. Arch Ophthalmol 2001;119:1417-1436. (1)Alban et al. Retningslinier for udarbejdelse af økonomiske analyser aflægemidler. Bilag 1 i Sundhedsministeriet. Udfordringer på lægemiddelområdet.Betænkning afgivet af Sundhedsministeriets Medicinudvalg.Sundhedsministeriet, København, juni 1998. (2)Algvere PV, Berglin L, Gouras P, Sheng Y. Transplantation of fetal retinalpigment epithelium in age-related macular degeneration with subfovealneovascularization. Graefes Arch Clin Exp Ophthalmol 1994;232:707-16.(3)Allikmets R et al. Mutation af the Stargardt disease gene (ABCR) in agerelatedmacaular degeneration. Science 1997; sept. 277(5333):1805-7. (4)The Alpha-Tocopherol BCCPSG. The effect of Vitamine E and beta caroteneon the incidence of lung cancer and other cancers in male smokers. NEng J Med. 1994;330(15):1029-35. (5)Armbrecht et al. Is cataract surgery justified in patients with age relatedmacular degeneration? A visual function and quality of life assessment. BrJ Ophthalmol 2000;84:1343-1348. (6)Augsburger JJ. External beam radiation is not effective in the treatment ofage-related macular degeneration. Arch Ophthalmol 1998;116:1509-11.(7)Berger J. Wavelength considerations for laser prophylaxis in AMD. Ophthalmol2000;107:1019-1021. (8)Bird AC, Bressler NM, Bressler SB et al. An international classificationand grading system for age-related maculopathy and age-related maculardegeneration. Surv Ophthalmol 1995;39:367-374. (9)Blumenkranz MS. TAP 24-months topline data. Http://www.visudyne.wwwepposium.com/pw/html/index.html(10)Blumenkranz MS. ARVO 2001, Fort Lauderdale, FL, USA. Http://www.visudyne.wwwepposium.com (11)79
Blumenkranz MS. Status of photodynamic drugs and photodynamic trials,Vitreoretinal update/subspeciality day. San Fransisco 1999, AmericanAcademy of Ophthalmology. (12)Bressler NM, Bressler SB, West SK et al. The grading and prevalence ofmacular degeneration in Chesapeake Bay watermen. Arch Ophthalmol1989;107:847-852. (13)Bressler NM, Munoz B, Maguire MG. Five-year incidence and disappearanceof drusen and retinal pigment epithelial abnormalities (WatermanStudy). Arch Ophthalmol 1995;113:301-308. (14)Brown GC. Vision and Quality-of-life. Trans Am Ophth Soc 1999;97:473-511. (15)Brown GC. Incremental cost effectiveness af laser photocoagulation forsubfoveal choroidal neovascularization. Ophthalmology 2000;107:1374-1380. (16)Canadian Coordinating Office for Health Technology Assessment. Guidelinesfor economic evaluation of pharmaceuticals: Canada. 2’nd ed.Ottawa: CCOHTA; 1997. http://www.ccohta.ca (17 )Choroidal Neovascularization Prevention Trial Research Group. Laser treatmentin eyes with large drusen: short-term effects seen in a pilot randomizedclinical trial. Ophthalmology 1998;105:11-23. (18)D’Amato RJ, Loughnan MS et al. Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci USA. 1994;91(9):4082-5. (19)Desai P, Reidy A, Minassian C et al. Gains from cataract surgery: Visualfunction and quality of life. Br J Ophthalmol 1996;80:868-873. (20)Della NG, Wilson DJ, Klein ML. Clinical and pathologic effects of gridmacular laser in aged primate eyes containing drusen. IOVS 1997;38(suppl 4):s 18. (21)Drummond et al. Methods for the economic evaluation of health care programmes.Second edition. Oxford Medical Publications, Oxford UniversityPress, Oxford, 1997. (22)Duvall J, Tso MOM. Cellular mechanisms of resolution of drusen afterlaser photocoagulation: an experimental study. Arch Ophthalmol 1985;103:694-703. (23)Eckardt C, Eckardt U, Conrad HG. Macular rotation with and withoutcounter-rotation of the globe in patients with age-related macular degeneration.Graefes Arch Clin Exp Ophthalmol 1999;237:313-325. (24)Evans JR. Gingko biloba extract for age-related macular degeneration.(CochraneReview). The Cochrane Library 2000;(3):Oxford updatesoftware. (25)80
Page 2 and 3:
Fotodynamisk behandling afkarnydann
Page 9 and 10:
som rammer erhvervsaktive yngre men
Page 12 and 13:
1IntroduktionAldersrelateret macula
Page 14:
som følge af AMD - vil nå op på
Page 17 and 18:
pension af lipidomsluttede mikrosf
Page 19 and 20:
hos 61% af de behandlede patienter,
Page 22 and 23:
3PatientenGrundsygdommen ARM medfø
Page 24:
nelse, helt op til 87% inden for 5
Page 27 and 28:
TABEL 1Personaletimer pr. behandlin
Page 29 and 30: man derfor antager, at de fleste pa
Page 31 and 32: eview af litteratur om incidens af
Page 33 and 34: ehandlede vil have et større overs
Page 35 and 36: ode bevirker diskontering, at forho
Page 37 and 38: sidste rest af centralsyn svinder p
Page 39 and 40: give en behandling med en relativt
Page 42 and 43: 7Ordliste, anvendte forkortelser og
Page 44: QALYretinaserøsstromasubfovealsubr
Page 47 and 48: Communities Study, fandt man en hø
Page 49 and 50: Når AMD medfører symptomer, er de
Page 51 and 52: Bilag 2Eksperimentelle eller uvalid
Page 53 and 54: tion af antioksidanter og zink. Der
Page 55 and 56: TermoterapiI mindre, ukontrollerede
Page 57 and 58: Bilag 3Epidemiologi: Tidligere stud
Page 59 and 60: Bilag 4Incidensopgørelse af potent
Page 61 and 62: henvist til vurdering i hospitalsre
Page 63 and 64: patientbetingede grænser for hvor
Page 65 and 66: Bilag 5Syn, funktionsevne og helbre
Page 67 and 68: den), afstandssynet (Snellen’s bo
Page 69 and 70: ste øje, eller et sammenligneligt
Page 71 and 72: Bilag 6Produktinformation (ved Nova
Page 73 and 74: Udtrængning fra karsystemet (ektra
Page 75 and 76: under ”Særlige advarsler og fors
Page 77 and 78: ProteinbindingI humant fuldblod fin
Page 79: fortyndes med 5% Glucose til injekt
Page 83 and 84: Klein R, Clegg C, Cooper LS et al.
Page 85 and 86: MPSG. Subfoveal neovascular lesions
Page 87 and 88: TAP Study Group. Photodynamic Thera
show all

Kun elektronisk udgave - Sundhedsstyrelsen

Create successful ePaper yourself

Delete template?

Save as template?